Bio Spectrum - September 2021Add to Favorites

Get Bio Spectrum along with 5,000+ other magazines & newspapers

Try FREE for 7 days

bookLatest and past issues of 5,000+ magazines & newspapersphoneDigital Access. Cancel Anytime.familyShare with 4 family members.

1 Year$99.99

bookLatest and past issues of 5,000+ magazines & newspapersphoneDigital Access. Cancel Anytime.familyShare with 4 family members.
(Or)

Get Bio Spectrum

1 Year $10.99

Save 7%
book12 issues starting from December 2021 phoneDigital Access. Cancel Anytime.

Buy this issue $0.99

bookSeptember 2021 issue phoneDigital Access.

Gift Bio Spectrum

  • Magazine Details
  • In this issue

Magazine Description

In this issue

While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.

  • cancel anytimeCancel Anytime [ No Commitments ]
  • digital onlyDigital Only
RECENT STORIES FROM BIO SPECTRUMView All